Reassessing serum urate targets in the management of refractory gout: Can you go too low?

Current Opinion in Rheumatology

Volumn 21, Issue 2, 2009, Pages 138-142

  Hershfield, Michael S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Febuxostat; Gout; Hypouricemia; Pegloticase; Tophus

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; FEBUXOSTAT; PEGLOTICASE; UNCLASSIFIED DRUG; URATE; URIC ACID;

DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GOUT; HUMAN; HYPOURICEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

CRYSTALLIZATION; GOUT; GOUT SUPPRESSANTS; HUMANS; OXIDATIVE STRESS; URIC ACID;

EID: 62349113174     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283257b83     Document Type: Review

References (40)

1. Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J (Clin Res Ed) 1987; 294:1504-1505.
2. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008; 20:198-202.
3. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005; 44:1038-1042.
4. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006; 33:104-109.
5. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007; 66:1269-1270.
6. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001; 13:240-244.
7. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007; 57:822-829.
8. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31:1575-1581.
9. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 2007; 9:258-264.
10. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46:1372-1374.
11. Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007; 26:1459-1465.
12. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68:51-56.
13. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
14. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28:577-580.
15. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321-325.
16. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66:1056-1058. The results of this relatively small study imply that the time required to resolve tissue MSU deposits reflects the burden of MSU that had accumulated prior to ULT.
17. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47:356-360.
18. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-2461.
19. Sundy JS, Becker MA, Baraf HSB, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycolconjugated uricase) in patients with treatment-failure gout. Arthritis Rheum 2008; 58:2882-2891.
20. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57:1324-1328. A timely review and analysis of the literature related to targets for ULT.
21. Hershfield MS, Sundy JS. Urate oxidase (Uricase). In: Wortmann RL, Schumacher HR, Becker MA, Ryan LM, editors. Crystal-induced arthropathies. New York, USA: Taylor & Francis; 2006. pp. 401-410.
22. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006; 8:R12.
23. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56:1021-1028.
24. Lasaga AC, Luttge A. Variation of crystal dissolution rate based on a dissolution stepwave model. Science 2001; 291:2400-2404.
25. Erwin CL, Nancollas GH. The crystallization and dissolution of sodium urate. J Crystal Growth 1981; 53:215-223.
26. Wortmann RL. Effective management of gout: an analogy. Am J Med 1998; 105:513-514.
27. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78:6858-6862.
28. Pacher P, Beckman J, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Res 2007; 87:315-424.
29. Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006; 108:527-531.
30. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007; 166:561-567. A prospective case-control study, which found that normal, but relatively low plasma urate levels preceded the onset of neurologic symptoms of Parkinson's disease. The authors review other evidence that uric acid is neuroprotective.
31. Koch M, De Keyser J. Uric acid in multiple sclerosis. Neurol Res 2006; 28:316-319.
32. Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993; 6:119-126.
33. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69:1418-1423. A cross-sectional observational study, which demonstrates that high normal levels of sUA are associated with an increased burden of cerebral ischemic disorder in older adults. The authors discuss the seemingly contradictory properties of uric acid, being both a 'neuroprotective' antioxidant and a risk factor for neurologic dysfunction.
34. Santos CX, Anjos El, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 1999; 372:285-294.
35. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300:924-932. A randomized, double blind cross-over trial demonstrating that allopurinol treatment reduced blood pressure in children with essential hypertension and sUA more than 6 mg/dl. Although subject to a number of limitations, the study provides intriguing evidence in humans that elevated urate levels might play a causal role in early hypertension.
36. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58:623-630. This epidemiologic study evaluated the prognostic value of sUA levels in a large cohort of men and women at high risk of cardiovascular disease. The risk of death was estimated to increase by 39% for every 1 mg/dl increase in sUA.
37. Strasak AM, Kelleher CC, Brant U, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28 613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125:232-239. This large epidemiologic study confirms the association of cardiovascular risk with urate levels in the upper normal range. The lowest quintile of sUA concentration was associated with the lowest risk. These results, and those of reference [36•], are useful in gauging whether inducing low urate levels might be of risk to gout patients with cardiovascular disease.
38. Raivio KO, Saksela M, Lapatto R. Xanthine oxidoreductase - role in human pathophysiology and in hereditary xanthinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York, USA: McGraw-Hill; 2001. pp. 2639-2652.
39. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164-173.
40. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/ day versus benzbromarone 100-200mg/day in patients with gout. Ann Rheum Dis 2008 [Epub ahead of print]. doi:10.1136/ard.2008.091462.